Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market. Learn more on RHHBY stock here.

Citibank, N.A., the depositary for the tender offer, advised Roche that a total of approximately 64,991,586 shares of Poseida’s common stock were validly tendered and not validly withdrawn in ...

ZURICH, Jan 8 (Reuters) - Roche (ROG.S), opens new tab on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics (PSTX.O), opens new tab ...

ZURICH (Reuters) -Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics , a specialist in complex immune cell therapies to treat ...

Citibank, N.A., the depositary for the tender offer, advised Roche that a total of approximately 64,991,586 shares of Poseida’s common stock were validly tendered and not validly withdrawn in the ...